Background: E-cadherin is a well-known tumor suppressor and its dysregulated expression correlates with tumor differentiation, metastasis and survival in esophageal squamous cell carcinoma (ESCC). p120 catenin is an Armadillo protein normally bound to E-cadherin in the cadherin-catenin complex at the adherens junction. Dysregulated expression and mislocalization of p120ctn affect the protective function of the complex. The objective of the present study was to evaluate the clinical significance of E-cadherin and p120ctn expression in ESCC.
dependent cell adhesion molecules. It is found mainly in epithelial cells and plays a key role in cell-cell interaction. Normally, E-cadherin functions as a mediator for tight intercellular adhesion, cell polarity and tissue architecture maintenance. 3 It is also a wellknown tumor suppressor, and downregulation of protein expression has been reported in many cancers including gastric, colorectal, breast and bladder cancers. [4] [5] [6] [7] [8] [9] [10] [11] [12] Genetic mutations, loss of heterozygosity and hypermethylation of its promoter are some factors causing dysregulated E-cadherin expression in carcinomas. 13, 14 In ESCC, reduced E-cadherin expression has been reported to correlate with tumor differentiation, metastasis and prognosis. [15] [16] [17] [18] [19] [20] [21] p120 catenin (p120ctn) was first identified to be an efficient tyrosine kinase substrate implicated in cell transformation by Src. It belongs to the Armadillo protein superfamily due to the possession of 10 Arm repeats. The human p120ctn gene (CTNND1) consists of 21 exons and makes up to 32 isoforms resulting from alternative splicing. Isoforms 1-4 differ from each other by four different start sites, and additional splicing products are formed by combinations of alternatively existing exons A (exon 18), B (exon 20) and C (exon 11). 22 p120ctn is ubiquitously expressed at high levels bound to E-cadherin on the plasma membrane directly at the juxtamembrane domain. It regulates cadherin turnover at the cell surface and its dissociation promotes cadherin internalization. It also stabilizes E-cadherin and rescues its function posttranslationally. 23 Besides cellular adhesive function, p120ctn is also involved in the regulation of cell motility through actin cytoskeleton remodeling via Rho, Rac and Cdc42 GTPases. [24] [25] [26] [27] Recent studies have indicated that p120ctn downregulation is correlated with poorly differentiated tumor and metastatic phenotype in certain cancers. 12, 28, 29 The purpose of the present study was to evaluate the clinical significance of E-cadherin and p120ctn expression and their inter-relationship in prognostication of ESCC.
MATERIALS AND METHODS

Patients and specimens
In this study, we recruited 71 patients with ESCC who had undergone esophagectomy between 1997 and 2005 at the Department of Surgery, University of Hong Kong Medical Centre, Queen Mary Hospital, Hong Kong. There were 50 men and 21 women; the mean age of the subjects was 65.0 ± 11.4 years (range 40-87 years). None of these patients had received neo-adjuvant chemotherapy or radiotherapy. Patient demographics and data concerning their operation, histopathology and long-term follow-up data were captured in a prospectively collected database. Specimens of the primary tumor and nontumor tissues from the proximal resection margins were obtained for storage and analyses.
Macroscopically, the site and size of the primary tumors were recorded. Standard blocks were taken and fixed in 10% formalin followed by embedding in paraffin wax. Histological sections were cut at 4 lm and stained with hematoxylin and eosin for light microscopy. Stained sections were reviewed and classified into different grades using World Health Organization (WHO) criteria. The cancers were staged according to TNM classification. 30 Representative blocks from the tumor and non-tumor tissue from each specimen were chosen for immunohistochemical study.
Immunohistochemistry
Both tumor and non-tumor tissue blocks were cut into 4-lm-thick sections and mounted on glass slides. Immunohistological staining was performed using the EnVision method as described previously. 31 Briefly, the sections were deparaffinized and rehydrated. Antigens were retrieved in preheated 0.2 M citrate buffer (pH 6) with microwave at 95°C for 12 min. Subsequently, endogenous peroxidase activity was blocked by 3% hydrogen peroxide at room temperature for 20 min. After washing with 1 · Tris buffered saline (TBS), nonspecific antigens were blocked with 2% bovine serum albumin (BSA, Sigma, St Louis, MO, USA) in TBS for 1 h. The sections were then incubated with primary antibodies overnight at 4°C. Primary antibodies included mouse monoclonal anti-E-cadherin (HECD-1) antibody (Cat No. 13 
Immunohistochemistry evaluation
Tissue sections were assessed by a pathologist (AKYL) using light microscopy. The grading of immunoreactivity was conducted according to staining intensity of tumor section compared with that of the corresponding non-tumor tissue. Staining intensity was classified into two categories: (a) complete loss/reduced expression and (b) preserved staining. Specifically for p120ctn staining activity, localization of the protein antigen was also documented and was classified as (a) absent/reduced membranous staining or (b) preserved membranous staining.
Statistical analysis v
2 test or FisherÕs exact probability test was used to assess the association between immunohistochemical reactivity and clinicopathological characteristics. The Kaplan-Meier method was employed for survival analysis and differences in survival were estimated using the log rank test. A P value less than 0.05 was considered statistically significant. All the statistical analyses were performed using SPSS 13.0 for Windows (Chicago, IL, USA).
RESULTS
Expression of E-cadherin and p120ctn in esophageal squamous cell carcinomas E-cadherin was observed mainly on the cell membrane of both non-tumor and tumor tissues ( Fig. 1 A,C). Complete loss or reduced E-cadherin expression was detected in 42.3% (30 of 71) of ESCC patients. However, p120ctn expression was well preserved in the majority of these patients (91.5%, 65 of 71); unlike E-cadherin, it was found on both cell membrane and cytoplasm of non-tumor cells (Fig. 1B) . Absent or reduced membranous p120ctn was observed in 33.8% (24 of 71) of ESCC patients (Fig. 1D) .
FIG. 1. Expression of E-cadherin and p120ctn in esophageal squamous cell carcinomas (ESCCs).
A Strong membranous expression of E-cadherin in nontumor tissue (·200). B Strong membranous expression of p120ctn in non-tumor tissue (·200). C Reduced expression of E-cadherin in tumor (·200). D Membranous loss and cytoplasmic accumulation of p120ctn in tumor (·400). E Heterogeneous expression of E-cadherin in dysplasia (·250). F Heterogeneous expression and localization of p120ctn in dysplasia (·250).
Relationship between E-cadherin and p120ctn expression and localization p120ctn membranous localization was related to membranous expression of E-cadherin. When it was found on the cell membrane, preserved membranous expression of E-cadherin was observed in 34 of 47 (72.3%) patients. But when p120ctn was lost or accumulated in the cytoplasm, membranous expression of E-cadherin was only found in 7 of 24 (29.2%) patients (P = 0.001) ( Table 1 ). This suggests that p120ctn membrane localization had a direct effect on membranous expression of E-cadherin.
Relationship between expression of E-cadherin and tumor differentiation in ESCC
Preservation of E-cadherin was noted in all welldifferentiated ESCC cases (100%, 12 of 12). In contrast, it was lost or detected only at low levels in most of the patients with poorly differentiated ESCC (73.3%, 11 of 15). A trend of increasing E-cadherin preservation with poorly to well-differentiated cancer patients was observed. A heterogeneous expression pattern was also detected in the regions of squamous dysplasia (Fig. 1E) . A significant relationship was found between E-cadherin expression and ESCC tumor differentiation (P = 0.001) ( Table 2) .
Relationship between localization of p120ctn and tumor differentiation in ESCC Of 12 well-differentiated ESCC patients, 2 (8.3%) were found to have membranous loss of p120ctn from membrane to cytoplasm. The p120ctn mislocalization was detected in the poorly and moderately differentiated cases in 91.7% (22 of 24) . Among cases with preserved membranous p120ctn protein, 89.4% (42 of 47) had moderately or well-differentiated tumors. Both gradual decrease in expression and increase in mislocalization of p120ctn protein were seen in squamous dysplasia (Fig. 1F) . Thus, the localization of p120ctn significantly correlated with tumor differentiation in ESCC (P = 0.008) ( Table 3) .
Relationship between p120ctn expression and lymph node metastasis
Among all the patients with preserved p120ctn expression, 66.2% (43 of 65) showed lymph node metastases (N1). In the cases with either complete loss or reduction in the expression of p120ctn, none (0%, 0 of 6) had lymph node metastasis (P = 0.003).
Relationship between E-cadherin and p120ctn expression and localization and clinicopathological features
No significant relationship was found when Ecadherin and p120ctn expression and localization were correlated with other clinicopathological features, including age, gender, smoking status, level of tumor, R category, pathological T-stage and Mstage, as well as pathological stage (Tables 2 and 3) .
Relationship between E-cadherin and p120ctn expression and localization and survival There were no significant differences in survival when patients were grouped and compared according to E-cadherin expression, p120ctn expression and p120ctn localization (P = 0.927, P = 0.700 and P = 0.183, respectively) ( Fig. 2 A,B,C ). All three factors had no significant predictive value in ESCC patient survival.
DISCUSSION
In the present study, we demonstrated that membranous expression of E-cadherin and p120ctn was found in non-tumor tissues of the esophagus, but complete loss or reduction of E-cadherin expression was shown in 42.3% of ESCC tumors. This is similar to results reported for other cancers. 8, 11, 21, 32 The reduced E-cadherin protein expression was associated with tumor differentiation (P = 0.001) but not the other clinicopathological parameters analyzed. In previous studies, downregulated E-cadherin expression was also observed according to the decreasing degree of tumor differentiation in ESCC. 15, 16 In esophageal adenocarcinoma, heterogeneous staining pattern with gradually diminishing expression of E-cadherin was seen from regions of metaplasia to dysplasia and to carcinoma, which indicated that the reduction of E-cadherin expression might also play a role in tumor progression in ESCC. 33 In the present study on ESCC, heterogeneous expression of E-cadherin was also noted in dysplastic mucosa adjacent to the carcinoma. E-cadherin expression is associated with higher metastatic rate in colorectal cancer, ESCC and head and neck squamous cell carcinoma. 8, 19, 34, 35 However, we could not demonstrate any significant relationship between E-cadherin expression level and lymph node metastasis (P = 0.332). It is worth noting that expression of N-cadherin promotes cell motility, invasion and metastasis, even in the presence of high level of E-cadherin in breast cancer. 10, 36 Thus, other cadherins such as N-cadherin may participate in intercellular adhesion compensating for the loss of Ecadherin function.
11 Another reason for the preserved level of E-cadherin in ESCC with lymph node metastasis might be that the detected proteins were the mutant with a larger molecular weight but no cell-cell adhesion ability. 37 p120ctn normally binds to the juxtamembrane domain of E-cadherins exerting a stabilizing effect in normal tissue. 23 In previous studies, p120ctn protein was detected in cell-cell boundaries in benign tumors and normal tissues, but in the cytoplasm in carcinomas. 9, 28, 38 In our IHC results, we did not show an overall decreased expression of p120ctn in most of the ESCC cases, but absent or decreased membranous expression and cytoplasmic accumulation were observed. Since p120ctn is a metabolically stable protein, its expression and half-life are not affected by the absence of cadherins and that might be the reason why our findings showed no significant relationship between E-cadherin expression and p120ctn expression (P = 0.233) (Data not shown). [39] [40] [41] In this study, mislocalization of p120ctn from cell membrane to cytoplasm was significantly associated with the loss or reduction in membranous E-cadherin in ESCC (P = 0.001). Recently, two mechanisms were proposed to explain such a relationship.
-(1)Mislocalization of p120ctn in cytoplasm leads to its incapability of interacting with E-cadherin and, consequently, loses its protective effect and eventually internalization and degradation of membranous E-cadherin. 41 Membranous derangement of p120ctn might be due to the p120ctn-microtubule network association directly or indirectly through the interaction with kinesin, 42 or an increased d-catenin pool that competes with p120ctn for the juxtamembrane domain on cadherins. 43 -(2)Insufficient capture of cytoplasmic p120ctn to cell membrane by downregulated E-cadherin leading to accumulation of excess p120ctn in the cytoplasm. 9, 35 In this study, p120ctn overall expression was preserved in all pathological N1 ESCC cases. This is in contrast to the findings of Bremnes et al. regarding lung cancer, 29 the difference perhaps being due to the fact that our samples are of a different cancer type that is not comparable, as p120ctn expression is tissue-and cell-type specific. 44 In addition, it has been suggested that different isoforms of p120ctn might display different functions. Aho and colleagues showed that certain isoforms of p120ctn did not induce branching phenotype while others did. Isoforms 4A and 1AB might have tumorsuppressor roles in skin cancer. 45 For our purposes, we used a primary antibody that recognized all four isoforms of p120ctn and therefore all detected proteins were indistinguishable. The differential expression profiles of different isoforms might account for the unexpected different results. It might also explain why there was no apparent significant relationship between p120ctn localization and pathological N-stage, although we had understood that the p120ctn-uncoupled E-cadherin was vulnerable to endocytosis and hence loses its cell-cell adhesive ability.
p120ctn has been reported as an independent prognostic marker in gastroesophageal adenocarcinoma. 28 In the present study, p120ctn localization in ESCC showed a significant relationship with tumor differentiation (P = 0.008). Membranous p120ctn protein was mostly preserved in well-differentiated tumors but lost or reduced in those poorly differentiated. It is also present occasionally in dysplastic mucosa, indicating that p120ctn localization might take part in tumor progression. However, no significant relationship between p120ctn expression and survival rate was noted in ESCC.
In conclusion, E-cadherin expression and p120ctn localization were associated with ESCC tumor differentiation and, in addition, p120ctn expression was related to lymph node metastasis. To our knowledge, this was the first time that a significant relationship between E-cadherin expression and p120ctn localization was demonstrated in ESCC. Despite the lack of prognostic value of E-cadherin and p120ctn in ESCC, assessment of both E-cadherin expression and co-localization of E-cadherin and p120ctn could hint at tumor progression. The prevalence of changes in these markers may be useful for planning treatment strategy for ESCC in future clinical management, and further studies on their roles in tumorigenesis are necessary.
